## AMENDMENTS TO THE CLAIMS

- (Previously presented) A composition for use in treating epithelial lesions formed of a combination of ingredients comprising:
  - 8-hydroxyquinoline in an amount of at least five percent of the composition by weight;
  - an escharotic chelatable metal agent bonded to said 8-hydroxyquinoline, the escharotic chelatable metal agent comprising a metal having an oxidation state of +2 present in a concentration of at least five percent by weight of the composition and less than an amount that produces an eschar in healthy mammalian tissues; and

## a carrier,

- the composition being a pharmaceutical grade material having a capacity for treating at least one type of lesion selected from the group consisting of venereal warts, male veruoca warts, lesions produced by the human papilloma virus, basal cell carcinoma, solar keratosis, Kaposi's sarcoma, eye cancer, sarcoids, sarcoma, malignant melanoma, rectal adenoma, histocytoma, sebaceous adenoma, lung cancer, breast cancer, and colon cancer.
- (Previously presented) The composition as set forth in claim 1, wherein the escharotic chelatable metal agent includes zinc in a molar ratio (8hydroxyquinoline:zinc) ranging from 1:1 to 1:3.
- (Previously presented) The composition as set forth in claim 2 wherein said molar ratio is about 1:2.
- (Previously presented) The composition as set forth in claim 1 wherein said escharotic chelatable metal agent comprises zinc.
- (Previously presented) The composition as set forth in claim 1 wherein said escharotic chelatable metal agent comprises zinc chloride in an amount ranging up to forty percent by weight of said composition by weight.

- (Previously presented) The composition as set forth in claim 1 wherein said escharotic chelatable metal agent comprises zinc chloride in an amount ranging up to twenty percent of said composition by weight.
- (Previously presented) The composition as set forth in claim 1 in combination with necrotic tissue from a lesion of said group produced by the action of said composition upon the lesion.

## 8-13. (Cancelled.)

- (Previously presented) The composition as set forth in claim 1, wherein said carrier comprises a gel.
- (Previously presented) The composition as set forth in claim 14 wherein said gel comprises a polyoxyalkylene ether derivative of propylene glycol.
- 16. (Currently amended) The composition as set forth in claim 1 wherein said carrier contains a penetrant <u>selected from the group consisting of lecithin and dimethyl</u> <u>sulfoxide</u>.
- 17. (Currently amended) The composition as set forth in claim  $1\underline{6}$  wherein said penetrant is lecithin.
- (Currently amended) The composition as set forth in claim 16 wherein said penetrant is dimethyl sulfoxide.
- (Currently amended) The composition as set forth in claim 1 wherein said carrier contains an antioxidant <u>selected from the group consisting of nordihydroguiaretic</u> acid and ascorbic acid.
- (Previously presented) The composition as set forth in claim 19 wherein said antioxidant includes nordihydroguiaretic acid.
- (Previously presented) The composition as set forth in claim 19 wherein said antioxidant includes ascorbic acid.

## 22-33 (Cancelled)

- (Currently amended) The composition as set forth in claim 1 wherein said carrier consists essentially of an antioxidant <u>selected from the group consisting of</u> nordihydrogujaretic acid and ascorbic acid.
- (Currently amended) The composition as set forth in claim 34 wherein said antioxidant consists essentially of an ascorbic acid ascorbate.
- (Original) The composition as set forth in claim 34 wherein the antioxidant consists essentially of nordihydroguiaretic acid.
  - 37-38 (Cancelled)
- (Previously presented) A composition for use in treating epithelial lesions formed of a combination of ingredients comprising:
  - 8-hydroxyquinoline in an amount of at least five percent of the composition by weight;
  - zinc chloride present in a concentration of at least five percent by weight of the composition and less than an amount that produces an eschar in healthy mammalian tissues; and

a carrier.

- 40. (Previously presented) The composition of claim 39, the 8-hydroxyquinoline and the zinc chloride being present in effective amounts for treating at least one type of lesion selected from the group consisting of venereal warts, male veruoca warts, lesions produced by the human papilloma virus, basal cell carcinoma, solar keratosis, Kaposi's sarcoma, eye cancer, sarcoids, sarcoma, malignant melanoma, rectal adenoma, histocytoma, sebaceous adenoma, lung cancer, breast cancer, and colon cancer.
- 41. (Previously presented) The composition as set forth in claim 39, wherein the 8-hydroxyquinoline and the zinc chloride are present in a molar ratio (8hydroxyquinoline:zinc) ranging from 1:1 to 1:3.
- 42. (Previously presented) The composition as set forth in claim 41, wherein the molar ratio is about 1:2.

- 43. (Previously presented) The composition as set forth in claim 41, wherein the 8-hydroxyquinoline is present in an amount ranging up to twenty percent.
- 44. (Previously presented) The composition as set forth in claim 39 in combination with necrotic tissue from a lesion of said group produced by the action of the composition upon the lesion.
- 45. (Previously presented) The composition as set forth in claim 39, wherein the carrier is a gel base.
- (Previously presented) The composition as set forth in claim 45, wherein the gel base is a polyoxyalkylene ether derivative of propylene glycol.
- (Currently amended) The composition as set forth in claim 39, wherein the carrier contains a penetrant <u>selected from the group consisting of lecithin and dimethyl</u> sulfoxide.
- 48. (Currently amended) The composition as set forth in claim  $\underline{47.39}$ , wherein the penetrant is lecithin.
- (Currently amended) The composition as set forth in claim 47 39, wherein the penetrant is dimethyl sulfoxide.
- (Currently amended) The composition as set forth in claim 39, wherein
  the carrier contains an antioxidant <u>selected from the group consisting of</u>
  nordihydroguiaretic acid and ascorbic acid.
  - 51-52 (Cancelled)